These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 15583844)
1. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. Xu Y; Voelter-Mahlknecht S; Mahlknecht U Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844 [TBL] [Abstract][Full Text] [Related]
2. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844 [TBL] [Abstract][Full Text] [Related]
5. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120 [TBL] [Abstract][Full Text] [Related]
6. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Rahmani M; Reese E; Dai Y; Bauer C; Kramer LB; Huang M; Jove R; Dent P; Grant S Mol Pharmacol; 2005 Apr; 67(4):1166-76. PubMed ID: 15625278 [TBL] [Abstract][Full Text] [Related]
7. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. Lee SM; Bae JH; Kim MJ; Lee HS; Lee MK; Chung BS; Kim DW; Kang CD; Kim SH J Pharmacol Exp Ther; 2007 Sep; 322(3):1084-92. PubMed ID: 17569822 [TBL] [Abstract][Full Text] [Related]
8. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors. Huang HM; Liu JC J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173 [TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
10. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463 [TBL] [Abstract][Full Text] [Related]
11. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Rabizadeh E; Merkin V; Belyaeva I; Shaklai M; Zimra Y Leuk Res; 2007 Aug; 31(8):1115-23. PubMed ID: 17267032 [TBL] [Abstract][Full Text] [Related]
12. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Rahmani M; Nguyen TK; Dent P; Grant S Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328 [TBL] [Abstract][Full Text] [Related]
13. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Kawano T; Horiguchi-Yamada J; Iwase S; Akiyama M; Furukawa Y; Kan Y; Yamada H Anticancer Res; 2004; 24(5A):2705-12. PubMed ID: 15517875 [TBL] [Abstract][Full Text] [Related]
14. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference. Bártová E; Harnicarová A; Pacherník J; Kozubek S Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941 [TBL] [Abstract][Full Text] [Related]
15. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442 [TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Vrana JA; Decker RH; Johnson CR; Wang Z; Jarvis WD; Richon VM; Ehinger M; Fisher PB; Grant S Oncogene; 1999 Nov; 18(50):7016-25. PubMed ID: 10597302 [TBL] [Abstract][Full Text] [Related]
17. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329 [TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270 [TBL] [Abstract][Full Text] [Related]
19. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
20. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine]. Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]